Compare Cytokinetics Inc (CYTK) vs Dow Inc (DOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Dow Inc — how do they compare? Cytokinetics Inc trades at $62.02 (market cap $8.50B), while Dow Inc trades at $28.52 (market cap $20.06B). The key difference: Dow Inc is far larger — about 2.4× Cytokinetics Inc's market cap, and Dow Inc pays a 5.04% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Dow Inc for 82 Days on average.
| CYTK | DOW | |
|---|---|---|
Market Cap | $8.50B | $20.06B |
Volume | 2,395,556 | 7,817,231 |
Sector | Health | Basic Materials |
52-Week High | $87.26 | $41.87 |
52-Week Low | $54.76 | $20.65 |
Typical Hold Time | 19 Days | 82 Days |
Enterprise Value | $8.60B | $35.75B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
DOW trades at $28.59, up 1.53% with bearish technical signals despite recent earnings beats. The chemical company faces fundamental challenges with negative net income margin (-3.13%) and declining revenue trends from $56.9B in 2022 to $40.0B in 2025. Analyst consensus shows mixed sentiment with 30.6% buy ratings but a $34.22 price target suggesting 20% upside. Recent dividend announcement of $0.35 provides income support while cash flow trends show operational improvement projected for 2026.
DOW presents a high-risk opportunity with significant valuation disconnect - low P/S ratio (0.48) contrasts with negative profitability metrics. The stock's appeal hinges on operational turnaround and margin recovery in 2026 projections. Key risks include persistent revenue declines, high debt levels (29.87% debt-to-asset ratio), and competitive pressures in chemicals sector. Current price near support at $28 creates tactical entry point for patient investors betting on management's execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →
